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in treatment and prophylaxis of patients with von Willebrand disease is approved 
from a pharmacoeconomic point of view.
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Objectives: The purpose was to estimate the financial consequences of reimburse-
ment of dasatinib in adult population with Ph+ ALL with resistance or intolerance 
to prior therapy in Poland. MethOds: The budget impact model was developed 
to evaluate the consequence for National Health Fund budget in Poland in case 
of reimbursement of dasatinib. Two scenarios were considered: with and with-
out dasatinib reimbursement in two-years’ time horizon (2015-2016). In scenario 
with reimbursement, dasatinib would be used instead the FLAM chemotherapy 
(fludarabine, cytarabine, mitoxantrone). Based on the Polish epidemiological data 
the target population – adult patients Ph+ ALL with resistance or intolerance to 
prior therapy – was estimated at 12 patients in one year (with range from 5 to 24). 
Direct medical costs: substances and their administration (assessed chemothera-
pies), monitoring, allogeneic hematopoietic stem cell transplantation (allo-HSCT), 
monitoring after allo-HSCT and palliative care were considered. All calculations 
were performed with the Excel model constructed for economic evaluation and 
budget impact assessment. Results: If the reimbursement of dasatinib is intro-
duced, the annual expenses from the budget of National Health Fund in Poland 
would increase by € 127,279 in the first year and € 189,224 in the second year of reim-
bursement. However, change from FLAM to dasatinib will decrease the necessity and 
length of hospitalization due to the different administration route. cOnclusiOns: 
Reimbursement of dasatinib in Poland will bring additional costs incurred by public 
payer, however, it will also increase the survival of patients with ultra-rare disease 
which is ALL and consequently improve their quality of life.
PSY29
Budget ImPact analYSIS of canacInumaB In the treatment of 
PatIentS WIth muckle–WellS SYndrome In the ruSSIan federatIon
Yagudina R, Kulikov A, Pochuprina A
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct budget impact analysis (BIA) of canakinumab treatment 
group comparing to symptomatic treatment in retrospective group of patients suf-
fering from Muckle–Wells Syndrome (MWS). MethOds: BIA was conducted of the 
canakinumab treatment group versus retrospective group with only symptomatic 
treatment. According to the expert opinion canakinumab treatment accompanied by 
vial sharing and it has been taken into consideration of drug cost therapy. Following 
direct medical costs were also included into analysis and based on expert opinion: 
administration costs, costs of diagnostic laboratory and instrumental procedure, costs 
of inpatient and outpatient visits, costs of treating MWS complications and costs for 
correction adverse events. One-year time horizon was used. Results: Cost of canaki-
numab therapy course was 40,830,937 RUB/ 668,220 EUR for 20 MWS patients within 
1 year. The difference in the required budget funds between canakinumab treatment 
group and retrospective group with symptomatic treatment was 38,787,076 RUB/ 
634,771 EUR for 20 patients within 1 year. Decrease of direct medical costs (excluding 
costs for drug therapy) was obtained in canakinumab treatment group and amounted 
763,705 RUB/ 12,498 EUR for 20 patients within 1 year due to a lower frequency of 
inpatient and outpatient visits, complications of MWS and lower administration costs 
in group treated with canakinumab. cOnclusiOns: Usage of canakinumab in the 
treatment of patients with MWS led to budget spending. However, good efficacy of 
canakinumab helped to reduce direct medical costs for 763,705 RUB/12,498 EUR for 
20 patients within 1 year in canakinumab treatment group.
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Objectives: Evaluate the current prescription trend in Italy and estimate the 
impact of alternative market hypothesis including the introduction of inflixi-
mab biosimilars. MethOds: Biologics currently indicated for psoriasis include 
tumor necrosis factor (TNF)-α inhibitors adalimumab, etanercept, and infliximab, 
as well as the interleukin-12/23 inhibitor ustekinumab. A deterministic Markov 
model was developed to simulate the evolution of bio-naïve psoriatic patients 
in Italy for 3 years. Event rates (mortality, malignancies, infections and MACEs) 
and persistence curves, were modeled for each biologic drug used in first, second 
and third line, basing on published data. Hospitalization costs were calculated 
as average of Italian DRGs weighted for event-related frequency. The cost of a 
dermatological visit was considered every two months and in case of therapy 
switch. All costs were calculated from the perspective of NHS. The current Italian 
market mix of biologic treatments was compared with the total substitution of 
infliximab with its biosimilars combined with ustekinumab increasing its mar-
ket share to 40% at the expenses of the remaining biologics, proportionally to 
their current shares. Results: In the next three years, 515 bionaive patients are 
expected to start a new biological treatment annually. Total cost results in about 
45.7 million Euro for 3 years in the current scenario corresponding to 15,148 Euro/
patient yearly. Increasing in ustekinumab market shares and the introduction of 
infliximab biosimilars lead to estimated annual savings of about 670 Euro/patient 
(1.7 million Euro in 3 years). Cost of biologic therapy is the main driver, while der-
matological visits and adverse events management represent less than 1% of the 
total cost. cOnclusiOns: Biological treatment cost of psoriasis depends almost 
completely from pharmacological therapy. Changes in the current prescription 
validation. Further research about the value and accuracy of existing instruments 
in clinical practice is required.
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Objectives: The UK population is ageing, and the prevalence of obesity is increas-
ing. To assess the likely impact of these two demographic trends, we used a sto-
chastic all-cause, cause of death mortality model to determine changes in likely 
age of death associated with different body mass index (BMI) values in older 
adults. MethOds: The Sonata Vivo model adjusts population baseline mortality 
for known risk factors to calculate the mean age of death and most likely causes 
of death for an individual, and has been validated against long-term cohorts in the 
UK and USA. We used the model to calculate the difference in mean ages of death 
at BMIs of 27, 33, 37 and 42 compared with a BMI of 22 in men and women aged 55 
to 90. We assumed all subjects were non-smokers with population average values 
for blood pressure, cholesterol and alcohol consumption. Results: In adults aged 
55 years at baseline, increasing BMI from 22 to 42 was associated with a decrease 
in mean age of death of 1.93 years in women and 1.89 years in men. The absolute 
difference in life expectancy across the BMI range decreased with increasing age 
at baseline, to 0.34 years in women and 0.15 years in men aged 90. As expected, 
the model predicts a longer life expectancy in women than men at each age and 
BMI, but the relative difference between genders was smaller in those with a BMI 
of 42 than in those with a BMI of 22. Analysis by likely cause of death in 55 year old 
adults showed the main impact of obesity was on cardiovascular (CVD) and cancer 
deaths in women, and CVD and endocrine deaths in men. cOnclusiOns: Obesity 
is likely to reduce life expectancy by up to 2 years in older adults in the UK, mainly 
from increased CVD mortality.
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Objectives: The aim of this study was to evaluate the Budget Impact (BI) of 
treatment of Crohn’s disease with adalimumab (ADA) from the perspective of the 
Brazilian Private Health Care System (BPHCS) over a 5 year time period. MethOds: 
An epidemiological model based on the Private Health Care System population, 
DataSUS database and published literature was developed to estimate eligible 
patients in the next five years. The BI was simulated comparing the current sce-
nario (patients treated with intravenous infliximab [IFX]) with a new scenario 
(the introduction of ADA for Crohn’s disease treatment), BPHCS perspective. The 
market-share for ADA starts at 20% during the first year and rises to 80%. Dose per 
application, number of vial/syringe, cost of application and median of weight were 
based on scientific literature. The drug prices were based on Factory Prices plus 
18% taxes from CMED. A deterministic sensitivity analysis (DSA) was performed 
to determinate the impacts in results. Results: 10,035 patients were eligible 
for treatment with either IFX or ADA over the five years of analysis. In the base 
case scenario, the Budget Impact simulation presented a decrease of total cost 
by R$1,942,434.38 in the first year and reached a decrease of R$9,089,493.93 in the 
fifth year. The cumulative economic savings for the five years in the simulation 
with ADA introduction was R$26,879,457.87. In deterministic sensitivity analysis 
cost per vial of IFX, cost per syringe of ADA and market-share of patients were the 
most important variables that impacted results. A majority of DSA scenarios indi-
cated that treatment with ADA provides cost savings. cOnclusiOns: The utiliza-
tion of ADA may generate economic savings for the Brazilian Private Health Care 
System that may allow more eligible patients with Crohn’s disease to be treated 
with ADA.
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Objectives: To conduct a budget impact analysis of treatment and prophylaxis 
of acute bleedings among patients with von Willebrand disease using blood clot-
ting factor concentrates (clotting factor VIII + von Willebrand factor) in the Russian 
Federation. MethOds: Clinical effectiveness assessment was based on the results of 
modeling of the treatment and prophylaxis of patients with von Willebrand disease 
using blood clotting factor concentrates (clotting factor VIII + von Willebrand factor) 
within one year (time horizon). The required data was obtained from literature review 
within PubMed and E-library, and from experts in hematological healthcare centers 
in Russia. Cost analysis included assessment of direct and indirect costs that can 
be associated with analyzed schemes of treatment (“No prophylaxis”, “Prophylaxis 
¹1” – median purity concentrate VWF:RCo/FVIII= 0,5/1, “Prophylaxis ¹2” - high purity 
concentrate VWF:RCo/FVIII= 2,5/1, “Prophylaxis ¹3” - high purity concentrate VWF:RCo/
FVIII= 0,9/1). Cost data was based on median prices for medicines and medical services 
in National healthcare system in the Russian Federation. Results: In case of switch-
ing from regimens: “No prophylaxis”, “Prophylaxis ¹1”, “Prophylaxis ¹2”, to the regular 
preventive administration with the scheme “Prophylaxis ¹3” total costs per all popula-
tion within one year can be reduced by 21906000 rubles ($ 396 360), 22143000 rubles 
($ 400 648) and 5752000 rubles ($ 104 075), respectively. cOnclusiOns: Obtained 
results demonstrates that the use of high purity concentrate VWF:RCo /FVIII= 0,9/1 
